.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Baxter
Cerilliant
McKesson
Covington
Argus Health
Queensland Health
Daiichi Sankyo
Deloitte

Generated: November 23, 2017

DrugPatentWatch Database Preview

Swedish Orphan Company Profile

« Back to Dashboard

What is the competitive landscape for SWEDISH ORPHAN, and when can generic versions of SWEDISH ORPHAN drugs launch?

SWEDISH ORPHAN has two approved drugs.

There is one US patent protecting SWEDISH ORPHAN drugs.

There are twenty patent family members on SWEDISH ORPHAN drugs in twenty countries and three supplementary protection certificates in three countries.

Summary for Swedish Orphan

International Patents:20
US Patents:1
Tradenames:1
Ingredients:1
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-004Jun 13, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-002Jan 18, 2002RXYesNo► Subscribe► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-003Jan 18, 2002RXYesYes► Subscribe► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-001Jan 18, 2002RXYesNo► Subscribe► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
SUSPENSION;ORAL206356-001Apr 22, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Swedish Orphan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-001Jan 18, 2002► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-002Jan 18, 2002► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-003Jan 18, 2002► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-003Jan 18, 2002► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-002Jan 18, 2002► Subscribe► Subscribe
Swedish Orphan
ORFADIN
nitisinone
CAPSULE;ORAL021232-001Jan 18, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Swedish Orphan Drugs

Country Document Number Estimated Expiration
Spain2566787► Subscribe
Mexico2013014567► Subscribe
New Zealand618332► Subscribe
Canada2838039► Subscribe
Japan6038132► Subscribe
HungaryE027304► Subscribe
San MarinoT201600097► Subscribe
Japan2014517067► Subscribe
Cyprus1117273► Subscribe
Serbia54632► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Swedish Orphan Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0024France► SubscribePRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221
00198Netherlands► SubscribePRODUCT NAME: NITISINONE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/303/001-003 20050201
C/GB05/030United Kingdom► SubscribePRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Baxter
Mallinckrodt
Cipla
Express Scripts
Accenture
Johnson and Johnson
Fish and Richardson
UBS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot